Search

Arvinas Inc

Open

SectorGezondheidszorg

8.9 -0.45

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.69

Max

9.02

Belangrijke statistieken

By Trading Economics

Inkomsten

227M

169M

Verkoop

234M

250M

K/W

Sectorgemiddelde

33.654

57.002

EPS

2.58

Winstmarge

67.841

Werknemers

246

EBITDA

216M

159M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+59.49% upside

Dividenden

By Acuity

Volgende Winsten

4 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

45M

565M

Vorige openingsprijs

9.35

Vorige sluitingsprijs

8.9

Nieuwssentiment

By Acuity

61%

39%

296 / 340 Rangschikking in Healthcare

Arvinas Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 aug 2026, 19:46 UTC

Arvinas Inc. shares are higher today, maintaining a position above their 20-day moving average and near the upper end of their one-month range.

11 aug 2026, 19:26 UTC

Arvinas Inc. shares are trading lower as the Pharmaceuticals sub-sector declines, despite a peak shortly after the market opened. No specific news was identified.

10 aug 2026, 19:56 UTC

News

Analysts updated ratings on Arvinas Inc, with Citigroup lowering its target to $21 and Evercore ISI reducing its target to $14. Shares are trading higher.

7 aug 2026, 19:51 UTC

Arvinas Inc is rising amid a broader market rally, with no specific company news driving the move. The stock remains above its 20-day moving average.

6 aug 2026, 19:46 UTC

News

Arvinas Inc reported earnings per share of $2.58, exceeding estimates. Revenue reached $249.7 million, driving shares higher in Thursday's session.

5 aug 2026, 20:03 UTC

News

Arvinas shares are lower following Wells Fargo's downgrade to Equal-Weight and a price target cut to $11, despite Wedbush raising its target to $12.

4 aug 2026, 20:02 UTC

Social Media
News

Arvinas Inc shares rose following strong Q2 results, with EPS of $2.58 and revenue of $249.7 million, surpassing analyst expectations. BTIG reiterated its Buy rating.

3 aug 2026, 19:46 UTC

News

Arvinas Inc. shares are lower today, continuing a downward trend since Friday. Barclays raised its price target from $18.00 to $20.00 while maintaining an "overweight" rating.

31 jul 2026, 20:06 UTC

Arvinas Inc shares are declining amid broader market trends and rising Treasury yields. The stock remains below its 20-day moving average.

29 jul 2026, 16:36 UTC

Arvinas shares are lower today, trading near the lower end of their one-month range amid rising oil prices and inflation concerns.

28 jul 2026, 20:06 UTC

Arvinas Inc's shares are lower today, reflecting broader market trends amid a significant decline in Asian indices, particularly the Nikkei 225.

24 jul 2026, 19:26 UTC

Arvinas Inc. shares are lower amid a broader market decline influenced by falling crude oil prices, now near the lower end of their one-month range.

22 jul 2026, 20:06 UTC

Arvinas Inc. shares are near unchanged amid routine trading and cautious market sentiment ahead of the Federal Reserve meeting.

21 jul 2026, 20:06 UTC

Arvinas Inc shares are higher during Tuesday's session, tracking gains in the Nasdaq 100 Index amid strong technology sector performance. No specific news was identified.

Peer Vergelijking

Prijswijziging

Arvinas Inc Prognose

Koersdoel

By TipRanks

59.49% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 14.37 USD  59.49%

Hoogste 21 USD

Laagste 8.68 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Arvinas Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

12 ratings

5

Buy

7

Hold

0

Sell

Sentiment

By Acuity

296 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
help-icon Live chat